D-Wave, Quantum

D-Wave Quantum: CHIPS Funding Access, a 21% Revenue Gain and Three Trimmed Targets

Published on 11/19/2026 at 17:11 | Editorial boerse-global.de
D-Wave can tap up to $100M under the CHIPS Act, but Q3 bookings fell 19% and a securities class action has been filed against the company.
D-Wave Quantum Illustration mit AI erstellt.

D-Wave Quantum disclosed on November 10 that it has gained access to as much as $100 million under the US CHIPS and Science Act — a sum that comes with strings attached, tied to milestones and conditions the company must satisfy. The news landed alongside the quantum computing firm's quarterly results, and the stock moved up 4.6% to €7.32 on the day.

The funding access formed one part of the company's broader third-quarter 2026 update. Revenue for the period came in at $4.5 million, a 21% increase over the same quarter a year earlier. The bottom line remained deeply in the red: a net loss of $48.2 million, with the adjusted loss before interest, taxes, depreciation and amortization at $37.7 million.

Bookings Tell Two Different Stories

Where the headline numbers diverge is in orders. For the first nine months of 2026, D-Wave put bookings at $37.4 million — a 611% jump from the prior-year period. Remaining performance obligations, the work still to be delivered, reached $38.3 million at the end of the third quarter, up 1,221% year over year.

Should investors sell immediately? Or is it worth buying D-Wave Quantum?

The quarterly picture cuts against that run. Bookings for the three-month stretch fell 19% to $1.9 million, a softness that coverage of the post-earnings share price decline flagged as a drag.

Analysts Cut Targets, Keep Their Ratings

Two brokerages trimmed their price targets on November 11 while leaving their bullish stances intact. Canaccord Genuity lowered its target to $31 from $35 and maintained a buy rating. Evercore ISI cut its target to $27 from $37 and kept an outperform rating. A third research house also reduced its target while retaining a buy recommendation, leaving the three revised targets spread between $20 and $31.

Legal trouble is running in parallel. Pomerantz said on Tuesday that a securities class action had been filed in the US District Court for the Northern District of California against D-Wave Quantum and certain executives. Glancy Prongay Wolke & Rotter followed yesterday, noting that investors have until December 15, 2026 to seek appointment as lead plaintiff. The suit covers purchases made between February 26 and August 25, 2026.

The shares were up 2.9% in a later session as investors weighed the federal funding path against the softer quarterly bookings and the fresh litigation.

Ad

D-Wave Quantum Stock: New Analysis - 19 November

Fresh D-Wave Quantum information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated D-Wave Quantum analysis...

Disclaimer...
en | US26740W1099 | D-WAVE | boerse | 70537172 |